Published Research

The retatrutide literature has two distinct layers: in-vitro and preclinical pharmacology describing the triple-receptor profile, and clinical trial reports at phase 2 and beyond. This page maps that record and links to the primary sources.

Last editorial review: 2026-09-18 · Part of the Retatrutide research hub

Pharmacology literature

The foundational publication for this molecule is the 2022 Cell Metabolism report describing LY3437943 as a triple GIP, GLP-1 and glucagon receptor agonist. It sets out the receptor potencies, the design rationale and the preclinical profile, and it is the paper most other work cites when describing what the molecule is.

That publication is the correct starting point for any laboratory intending to reproduce or extend receptor-level work, because it defines the assay systems and reference comparators the rest of the field has largely adopted.

Clinical research reports

The clinical record entered the public literature with phase 2 reporting. The best-known publication is the 2023 New England Journal of Medicine phase 2 trial in obesity, alongside phase 2 reporting in type 2 diabetes in the general medical literature the same year.

These are investigational findings. Retatrutide has no marketing authorisation in the United Kingdom, and results at phase 2 do not establish either efficacy or safety conclusions of the kind that later-phase programmes are designed to test.

Reading the record critically

When assessing this literature it is worth separating three claims that are often merged: that the molecule activates three receptors (well supported in-vitro), that the triple profile produces a distinct metabolic signature (supported preclinically and, at phase 2, in humans), and that it is superior to dual agonism in any specific endpoint (a comparative claim that requires head-to-head evidence).

For that reason the comparative resources in this silo are written as descriptions of receptor pharmacology and study design rather than as claims of superiority.

Preclinical and translational research

Between the initial receptor pharmacology paper and the phase 2 clinical reports sits a body of preclinical work in rodent and non-human primate models, examining body weight, food intake, hepatic markers and glucose handling under chronic dosing. That literature is what links in-vitro receptor potency to the endpoints later tested in clinical trials.

Preclinical findings are informative for hypothesis generation but do not translate directly to human outcomes, and species differences in receptor distribution and metabolism mean that any specific numeric result from an animal study should be treated as model-specific rather than generalised.

Searching and tracking the literature

The most reliable way to follow new retatrutide publications is a standing PubMed search on the compound name and its research designation, combined with periodic checks of the ClinicalTrials.gov registry for newly registered or updated trials. Registry entries typically update well ahead of full manuscript publication, so they are a useful early signal even before results are reported.

When a new study appears, checking the study phase, the model system or population, and whether the comparator (if any) is placebo, an active peptide, or historical data is a quicker way to gauge its evidentiary weight than reading the abstract’s stated conclusions alone.

Model systems referenced across the literature

The retatrutide evidence base draws on several distinct model systems, each answering a different question. Transfected cell lines expressing a single human receptor with a cAMP or beta-arrestin readout answer questions about intrinsic receptor pharmacology. Primary or immortalised hepatocyte and adipocyte cultures answer questions about tissue-level response. Rodent models of diet-induced obesity or diabetes answer questions about integrated metabolic response under chronic dosing, and non-human primate studies sit closer still to human physiology before any clinical trial begins.

None of these systems is a substitute for another, and a claim made in one system does not automatically generalise to the next. Readers should note which system a given finding comes from before treating it as informative for a different question.

Study design features worth checking

When appraising any individual retatrutide study, a small number of design features carry a lot of weight: whether the study is randomised and, where feasible, blinded; whether the comparator is a vehicle or placebo control, an active reference compound, or only historical data; the sample size and whether it was pre-specified with a power calculation; and whether the primary endpoint was defined before or after the data were collected.

Phase 2 and later clinical trials are also registered in advance, and comparing the registered protocol on ClinicalTrials.gov with the eventual publication is a useful way to check whether outcomes were reported as originally planned or were adjusted afterwards.

Strength of the current evidence

Primary sources are peer-reviewed and publicly indexed. The comparative literature is thin: most comparisons between retatrutide and other incretin peptides are indirect rather than head-to-head.

References

1. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022 (PubMed)
2. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med, 2023 (DOI)
3. Indexed retatrutide publications (PubMed search listing)

Related Retatrutide research

• Mechanism of Action — How retatrutide engages the GIP, GLP-1 and glucagon receptors, and what that combined signalling is understood to do.
• Retatrutide vs Tirzepatide — Triple versus dual receptor agonism: how retatrutide and tirzepatide differ in receptor targets and study design.

Back to the Retatrutide research hub · Retatrutide research material · Certificates of analysis

Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.